Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 5/20 | 0.33 |
| ▸ | PRKCA | P17252 | 2/20 | 0.32 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.32 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.32 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetone SCHEMBL28329344 | 0.97 | MAPT (0.34) | MAPTMAPK1ALDH1A1FAAHHPGD | |
| SCHEMBL9227207 | 0.88 | MAPT (0.53) | MAPTMAPK1ALDH1A1FAAHHPGD | |
| SCHEMBL9225414 | 0.88 | MAPT (0.53) | MAPTMAPK1ALDH1A1FAAHHPGD | |
| SCHEMBL6226136 | 0.87 | PDE4A (0.32) | LMNAPDE4AL3MBTL1 | |
| SCHEMBL4604011 | 0.82 | PRKCA (0.33) | MAPTMAPK1ALDH1A1FAAHHPGD | |
| SCHEMBL4605190 | 0.82 | ALDH1A1 (0.34) | MAPTMAPK1ALDH1A1FAAHHPGD | |
| SCHEMBL4605186 | 0.82 | ALDH1A1 (0.34) | MAPTMAPK1ALDH1A1FAAHHPGD | |
| SCHEMBL4604007 | 0.80 | PRKCA (0.33) | MAPTMAPK1ALDH1A1FAAHHPGD | |
| SCHEMBL4603634 | 0.79 | MAPT (0.37) | MAPTMAPK1ALDH1A1FAAHHPGD | |
| SCHEMBL9228609 | 0.79 | MAPT (0.55) | MAPTMAPK1ALDH1A1FAAHHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190134179-A1 | COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE | VEDANTA BIOSCIENCES, INC. (US) | 2019-05-09 | — | — | US | claimed |
| US-10130695-B2 | Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease | VEDANTA BIOSCIENCES, INC. (US) | 2018-11-20 | — | — | US | claimed |
| WO-2018140687-A1 | USE OF SHORT CHAIN FATTY ACIDS FOR THE TREATMENT AND PREVENTION OF DISEASES AND DISORDERS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-08-02 | — | — | WO | claimed |
| US-20180214399-A1 | Use of short chain fatty acids for the treatment and prevention of diseases and disorders | Temple University--of the Commonwealth System of Higher Education | 2018-08-02 | — | — | US | claimed |
| US-20180000921-A1 | COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE | VEDANTA BIOSCIENCES, INC. (US) | 2018-01-04 | — | — | US | claimed |
| US-9764019-B2 | Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease | VEDANTA BIOSCIENCES, INC. (US) | 2017-09-19 | — | — | US | claimed |
| US-20160144014-A1 | COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE | VEDANTA BIOSCIENCES (US) | 2016-05-26 | — | — | US | claimed |
| EP-3019181-A2 | COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE | Puretech Ventures, LLC (US) | 2016-05-18 | — | — | EP | claimed |
| WO-2015006355-A2 | COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE | PURETECH VENTURES, LLC (US) | 2015-01-15 | — | — | WO | claimed |
| WO-2024151503-A1 | TREATMENT OF SKIN DISORDERS WITH SHORT CHAIN FATTY ACIDS | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024102902-A1 | METHODS OF TREATING OR PREVENTING LIVER DISEASES OR DISORDERS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20240009155-A1 | USE OF SHORT CHAIN FATTY ACIDS IN CANCER PREVENTION | UNIV TEMPLE (US) | 2024-01-11 | — | — | US | disclosed |
| US-20240009154-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE RELEASE SYNDROME | UNIV TEMPLE (US) | 2024-01-11 | — | — | US | disclosed |
| EP-4243803-A1 | USE OF SHORT CHAIN FATTY ACIDS IN CANCER PREVENTION | Temple University Of The Commonwealth System Of Higher Education (US) | 2023-09-20 | — | — | EP | disclosed |
| US-9764019-B2 | Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease | VEDANTA BIOSCIENCES, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160144014-A1 | COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE | VEDANTA BIOSCIENCES (US) | 2016-05-26 | — | — | US | disclosed |
| EP-3019181-A2 | COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE | Puretech Ventures, LLC (US) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015006355-A2 | COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE | PURETECH VENTURES, LLC (US) | 2015-01-15 | — | — | WO | disclosed |
| US-20050058611-A1 | Preventing and/or combating collagen fiber degradation induced under conditions of natural exposure to sunlight | L'OREAL (FR) | 2005-03-17 | — | — | US | disclosed |
| EP-1508328-A1 | Composition against the degradation of fibres of collagen induced in condition of natural solar exposure | L'OREAL (FR) | 2005-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240009154-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE RELEASE SYNDROME | TNF, IL6, IL2 | MAPT 3492/4885MAPK1 3188/4885ALDH1A1 1248/4885 |
| US-20050058611-A1 | Preventing and/or combating collagen fiber degradation induced under conditions of natural exposure to sunlight | COL14A1, COL2A1, COL1A1 | MAPT 306/4885MAPK1 3554/4885ALDH1A1 1316/4885 |
| US-20240009155-A1 | USE OF SHORT CHAIN FATTY ACIDS IN CANCER PREVENTION | FABP1, HDGF, HAVCR2 | MAPT 4860/4885MAPK1 551/4885ALDH1A1 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.